145 related articles for article (PubMed ID: 23650783)
1. Towards a tailored therapy in pancreatic cancer.
Maréchal R; Van Laethem JL
Acta Gastroenterol Belg; 2013 Mar; 76(1):49-56. PubMed ID: 23650783
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
Bird NT; Elmasry M; Jones R; Psarelli E; Dodd J; Malik H; Greenhalf W; Kitteringham N; Ghaneh P; Neoptolemos JP; Palmer D
Br J Surg; 2017 Mar; 104(4):328-336. PubMed ID: 28199010
[TBL] [Abstract][Full Text] [Related]
3. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
[TBL] [Abstract][Full Text] [Related]
4. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
[TBL] [Abstract][Full Text] [Related]
5. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Drouillard A; Puleo F; Bachet JB; Ouazzani S; Calomme A; Demetter P; Verset G; Van Laethem JL; Maréchal R
Br J Cancer; 2016 Nov; 115(10):1245-1252. PubMed ID: 27755532
[TBL] [Abstract][Full Text] [Related]
6. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
Poplin E; Wasan H; Rolfe L; Raponi M; Ikdahl T; Bondarenko I; Davidenko I; Bondar V; Garin A; Boeck S; Ormanns S; Heinemann V; Bassi C; Evans TR; Andersson R; Hahn H; Picozzi V; Dicker A; Mann E; Voong C; Kaur P; Isaacson J; Allen A
J Clin Oncol; 2013 Dec; 31(35):4453-61. PubMed ID: 24220555
[TBL] [Abstract][Full Text] [Related]
7. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
[TBL] [Abstract][Full Text] [Related]
9. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
[TBL] [Abstract][Full Text] [Related]
11. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine.
Phua LC; Goh S; Tai DWM; Leow WQ; Alkaff SMF; Chan CY; Kam JH; Lim TKH; Chan ECY
Cancer Chemother Pharmacol; 2018 Feb; 81(2):277-289. PubMed ID: 29196965
[TBL] [Abstract][Full Text] [Related]
12. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
[TBL] [Abstract][Full Text] [Related]
13. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies.
Svrcek M; Cros J; Maréchal R; Bachet JB; Fléjou JF; Demetter P
Histopathology; 2015 Feb; 66(3):457-62. PubMed ID: 25298108
[TBL] [Abstract][Full Text] [Related]
14. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
[TBL] [Abstract][Full Text] [Related]
15. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
16. dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
Xiong J; Altaf K; Ke N; Wang Y; Tang J; Tan C; Li A; Zhang H; He D; Liu X
Medicine (Baltimore); 2016 Mar; 95(10):e2936. PubMed ID: 26962792
[TBL] [Abstract][Full Text] [Related]
17. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy.
Yamada R; Mizuno S; Uchida K; Yoneda M; Kanayama K; Inoue H; Murata Y; Kuriyama N; Kishiwada M; Usui M; Ii N; Tsuboi J; Tano S; Hamada Y; Tanaka K; Horiki N; Ogura T; Shiraishi T; Takei Y; Katayama N; Isaji S
Pancreas; 2016; 45(5):761-71. PubMed ID: 26784908
[TBL] [Abstract][Full Text] [Related]
18. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.
Li D; Pant S; Ryan DP; Laheru D; Bahary N; Dragovich T; Hosein PJ; Rolfe L; Saif MW; LaValle J; Yu KH; Lowery MA; Allen A; O'Reilly EM
Pancreatology; 2014; 14(5):398-402. PubMed ID: 25278310
[TBL] [Abstract][Full Text] [Related]
19. Transport properties of pancreatic cancer describe gemcitabine delivery and response.
Koay EJ; Truty MJ; Cristini V; Thomas RM; Chen R; Chatterjee D; Kang Y; Bhosale PR; Tamm EP; Crane CH; Javle M; Katz MH; Gottumukkala VN; Rozner MA; Shen H; Lee JE; Wang H; Chen Y; Plunkett W; Abbruzzese JL; Wolff RA; Varadhachary GR; Ferrari M; Fleming JB
J Clin Invest; 2014 Apr; 124(4):1525-36. PubMed ID: 24614108
[TBL] [Abstract][Full Text] [Related]
20. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
Maréchal R; Mackey JR; Lai R; Demetter P; Peeters M; Polus M; Cass CE; Young J; Salmon I; Devière J; Van Laethem JL
Clin Cancer Res; 2009 Apr; 15(8):2913-9. PubMed ID: 19318496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
